TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
TST003 is a high affinity monoclonal antibody targeting Gremlin1, a member of the TGF-β superfamily. Gremlin1 protein is a highly conserved secreted protein and has shown to play important roles during embryonic development and promote epithelial mesenchymal transition. Gremlin1 is upregulated in multiple solid tumors. TST003 has demonstrated promising single agent and combination activities in patient-derived xenograft tumor models from the difficult-to-treat solid tumors resistant to checkpoint inhibitors including castration resistant prostate cancer and microsatellite stable colorectal cancer.
• First-In-Class Gremlin1 Targeting Antibody
• Target highly expressed in stromal cells in tumor microenvironment
• Targeting CPI resistant/ineligible solid tumors including Prostate cancer, NSCLC, CRC, ESCC, GC, PADC, Breast Cancer et
Researchers from Transcenta and Shanghai Jiao Tong University investigated the therapeutic potential of anti-Gremlin1 for prostate cancer in an aggressive mouse model of CRPC (Pbsn-Cre4; Ptenfl/fl; Trp53fl/fl GEMM) and patient derived xenograft (PDX), using TST003, a humanized Gremlin1-targeting antibody, and a surrogate antibody generated by Transcenta.